Topics:

Lung Cancer

ASCO Endorses Lung Cancer Guidelines for Molecular Testing

ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.

Lung Cancer

Inhibition of PD-1 with pembrolizumab was well tolerated and showed promising survival results in a large phase I trial of patients with advanced non–small-cell lung cancer (NSCLC).

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection.

Though surgery is the standard treatment for early-stage non-small-cell lung cancer, a new study suggests that stereotactic body radiotherapy offers lower immediate mortality and toxicity.

In this interview we discuss the recent CMS decision to cover low-dose CT screening for lung cancer in patients who fit specific criteria.

Men with high midlife cardiorespiratory fitness have a lower incidence of lung and colorectal cancer; however, this association was not seen for prostate cancer.

A retrospective analysis showed that crizotinib is highly active in lung cancer with ROS1 rearrangements, which are present in about 1% of lung adenocarcinomas.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.